![]() |
市场调查报告书
商品编码
1928862
月经疼痛缓解产品市场机会、成长要素、产业趋势分析及2026年至2035年预测Menstrual Pain Products Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035 |
||||||
全球月经疼痛产品市场预计到 2025 年将达到 84 亿美元,到 2035 年将达到 136 亿美元,年复合成长率为 5.1%。

这一增长主要源于全球范围内越来越多的女性报告月经不适,以及围绕月经健康的广泛讨论、减少污名化和提高健康素养。女性在应对月经越来越有信心,也更愿意选择符合自身舒适度、安全性和长期健康目标的解决方案。对药物止痛长期副作用的担忧也促使消费者关注强调天然、非侵入性和个人化照护的替代方法。同时,永续性因素也在影响购买决策,环保和有机产品也越来越受到消费者的青睐。这些行为、医疗和环境因素的综合作用持续重塑市场需求模式,并支持已开发经济体和新兴经济体市场的持续成长。
| 市场覆盖范围 | |
|---|---|
| 开始年份 | 2025 |
| 预测年份 | 2026-2035 |
| 起始值 | 84亿美元 |
| 预测金额 | 136亿美元 |
| 复合年增长率 | 5.1% |
传统店面销售药市场预计到 2025 年将创造 28 亿美元的收入,从 2026 年到 2035 年将以 5.5% 的复合年增长率成长。这些产品之所以继续被广泛使用,是因为消费者对其高度信任、能够快速缓解疼痛、在零售店广泛销售,以及药局和量贩店通路中拥有值得信赖的品牌的悠久历史。
预计到2025年,线上销售将占总销售额的67.1%。数位平台透过提供便利性、丰富的选择、极具竞争力的价格以及订阅配送选项,彻底改变了消费者获取产品的方式。直销模式和个人化购物体验的兴起,进一步巩固了线上分销的主导地位。
美国月经疼痛缓解产品市场预计到 2025 年将达到 15 亿美元,从 2026 年到 2035 年将以 6.2% 的复合年增长率成长。人们对月经健康状况的高度关注、强大的购买力以及先进的医疗保健基础设施,持续推动创新非药物疼痛管理解决方案的普及。
The Global Menstrual Pain Products Market was valued at USD 8.4 billion in 2025 and is estimated to grow at a CAGR of 5.1% to reach USD 13.6 billion by 2035.

Growth is strongly supported by a higher number of women reporting menstrual discomfort worldwide and by broader conversations around menstrual well-being that have reduced stigma and improved health literacy. Women are increasingly confident in managing their menstrual needs and are actively choosing solutions that align with comfort, safety, and long-term wellness goals. Concerns related to the long-term effects of drug-based pain relief have also shifted consumer interest toward alternative approaches that emphasize natural, non-invasive, and personalized care. At the same time, sustainability considerations are influencing purchasing decisions, as environmentally responsible and organic options gain greater acceptance. Together, these behavioral, medical, and environmental factors continue to reshape demand patterns and support consistent market growth across both developed and emerging economies.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $8.4 Billion |
| Forecast Value | $13.6 Billion |
| CAGR | 5.1% |
The traditional over-the-counter solutions segment generated USD 2.8 billion in 2025 and is forecast to grow at a CAGR of 5.5% from 2026 to 2035. These products continue to be widely used due to strong consumer confidence, rapid pain relief, broad retail availability, and the long-standing presence of trusted brands across pharmacy and mass-market channels.
The online sales segment accounted for 67.1% share in 2025. Digital platforms have transformed product access by offering convenience, broader assortments, competitive pricing, and recurring delivery options. The growth of direct-to-consumer models and personalized purchasing experiences has further strengthened the dominance of online distribution.
U.S. Menstrual Pain Products Market reached USD 1.5 billion in 2025 and is projected to grow at a CAGR of 6.2% from 2026 to 2035. High awareness of menstrual health conditions, strong purchasing power, and advanced healthcare infrastructure continue to encourage the adoption of innovative and non-drug pain management solutions.
Key companies active in the Global Menstrual Pain Products Market include Ovira, Angelini Pharma, ThermaCare, Nua, Chiaro Technology, Sumitomo Pharma America, Sirona Hygiene, Beurer, Welme, SteadySense, Cora, Matri, Livia by iPulse Medical, Meyer Organics, Thermaissance, and Bridges CHC. Companies operating in the Global Menstrual Pain Products Market are focusing on innovation, brand differentiation, and consumer engagement to strengthen their market position. Many players are investing in product development to deliver discreet, wearable, and technology-enabled solutions that improve comfort and usability. Strategic partnerships, especially with digital platforms and wellness communities, help brands expand visibility and reach targeted audiences. Firms are also emphasizing sustainability through responsible sourcing, eco-conscious packaging, and transparent manufacturing practices.